Dianthus Therapeutics 320% Year: What Investors Should Know as Stakes Shift
Dianthus Therapeutics has surged 320% over the past year, even as a large investor reduced its stake. This article di...
Knowing when to rebalance keeps your retirement plan on track. This intro covers indicators and a simple action plan.
17,694 articlesDianthus Therapeutics has surged 320% over the past year, even as a large investor reduced its stake. This article di...
Vice President JD Vance publicly pushed back on questions about President Trump's stock trading, arguing that the bil...
This earnings season produced a mix of wins and misses. We break down what worked what didn't, with actionable tips y...
Nvidia still dominates AI hardware, but the stock's sparkle has cooled. This article breaks down the three big reason...
Jim Cramer addressed a caller whose portfolio was heavily concentrated in NVIDIA, using the moment to discuss whether...
AI-driven productivity could redefine the path of interest rates. This article explores the mechanics, scenarios, and...
As markets swing on inflation relief and rate expectations, a well-known consumer staples leader sits at a bargain, o...
A trusted industrial name with a 27-year dividend growth streak trades lower amid volatility. We analyze why this sto...
Greg Abel is stepping into a part of the market Warren Buffett mostly left untouched. This article breaks down what A...
Small modular reactor stocks trading under $10 can look tempting, but prices don’t always reflect real value. This gu...
A LATAM tech titan posted stronger-than-expected growth in Q1 2026, yet its shares remain pressured. Investors are em...
Private credit fears spreading are reshaping risk in alternative investing. This article explains what’s driving thos...